Author: Louis Navellier and the InvestorPlace Research Staff

There are too many positives to hold it down for long.

If you’ve been sitting on the sidelines to buy, now’s as good an entry point as you’re probably going to get in the near future.

Its pullback is an opportunity that shouldn’t be missed.

The pandemic isn’t the only reason you should be looking at pharmaceutical stocks. Here are six pharma names to buy that will carry your portfolio boldly into the future.

It has an “A” ranking in my Portfolio Grader right now and it will blast off again, and soon.